New Study Shows That Cesium-131 From IsoRay Medical, Inc. Is an Effective, Well-Tolerated Brachytherapy Treatment for Prostate Cancer with Fewer Side Effects Than Other Medical Isotopes

CHICAGO--(BUSINESS WIRE)--Brian Moran, MD, founder and principal of the Chicago Prostate Cancer Center (CPCC) presented the results of his two-year investigation into key characteristics of Cesium-131 at the 28th American Brachytherapy Society Annual Meeting, held in Chicago April 29th through May 1, 2007. Dr. Moran concluded that the medical isotope is effective and well-tolerated in its use to kill cancer cells in low dose (LDR) brachytherapy therapy for the treatment of prostate cancer.